Jefferies Financial Group Inc. Buys 2,254,219 Shares of Nkarta, Inc. (NASDAQ:NKTX)

Jefferies Financial Group Inc. lifted its position in Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 901.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,504,219 shares of the company's stock after buying an additional 2,254,219 shares during the quarter. Jefferies Financial Group Inc. owned about 3.55% of Nkarta worth $6,236,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in NKTX. JPMorgan Chase & Co. lifted its holdings in Nkarta by 138.7% during the 4th quarter. JPMorgan Chase & Co. now owns 2,537,922 shares of the company's stock valued at $6,319,000 after purchasing an additional 1,474,560 shares during the last quarter. Wasatch Advisors LP lifted its holdings in Nkarta by 37.4% during the 4th quarter. Wasatch Advisors LP now owns 2,520,909 shares of the company's stock valued at $6,277,000 after purchasing an additional 686,229 shares during the last quarter. Tang Capital Management LLC lifted its holdings in Nkarta by 252.9% during the 4th quarter. Tang Capital Management LLC now owns 2,293,719 shares of the company's stock valued at $5,711,000 after purchasing an additional 1,643,719 shares during the last quarter. Alyeska Investment Group L.P. lifted its holdings in Nkarta by 23.0% during the 4th quarter. Alyeska Investment Group L.P. now owns 1,334,696 shares of the company's stock valued at $3,323,000 after purchasing an additional 250,000 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Nkarta by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 1,181,357 shares of the company's stock valued at $2,942,000 after purchasing an additional 10,331 shares during the last quarter. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Nkarta Price Performance

NKTX traded up $0.05 on Thursday, hitting $1.81. 227,784 shares of the stock were exchanged, compared to its average volume of 1,062,223. Nkarta, Inc. has a 12 month low of $1.31 and a 12 month high of $8.23. The firm has a market capitalization of $128.43 million, a price-to-earnings ratio of -0.96 and a beta of 0.81. The business has a 50-day moving average of $1.81 and a two-hundred day moving average of $2.12.

Nkarta (NASDAQ:NKTX - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.01. Equities research analysts expect that Nkarta, Inc. will post -1.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on NKTX shares. Stifel Nicolaus cut their price target on Nkarta from $15.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, March 27th. HC Wainwright reissued a "buy" rating and set a $18.00 target price on shares of Nkarta in a report on Thursday, March 27th. William Blair reissued a "market perform" rating on shares of Nkarta in a report on Thursday, May 15th. Finally, Needham & Company LLC dropped their target price on Nkarta from $11.00 to $10.00 and set a "buy" rating for the company in a report on Thursday, May 15th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Nkarta presently has an average rating of "Buy" and a consensus price target of $14.67.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.